On Jan. 19, 2021, Adamis Pharma announced the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus. The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific recommendations on Chemistry, Manufacturing and Controls (CMC) and Clinical aspects to be included in the IND. The Company planned to seek government and/or non-government funding to study the treatment and prevention of COVID-19 with Tempol.